{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:57:12Z","timestamp":1779901032113,"version":"3.53.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.semarthrit.2010.09.002","type":"journal-article","created":{"date-parts":[[2010,12,18]],"date-time":"2010-12-18T04:14:57Z","timestamp":1292645697000},"page":"61-70","source":"Crossref","is-referenced-by-count":257,"title":["Anti-TNF Agents for Beh\u00e7et's Disease: Analysis of Published Data on 369 Patients"],"prefix":"10.1016","volume":"41","author":[{"given":"Aikaterini","family":"Arida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Fragiadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirini","family":"Giavri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2010.09.002_bib1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib2","first-page":"488","article-title":"Epidemiology of Adamantiades-Beh\u00e7et's disease","volume":"150","author":"Zouboulis","year":"1999","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib3","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.24146","article-title":"Behcet's syndrome is not so rare: why do we need to know?","volume":"58","author":"Yazici","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib4","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib5","first-page":"1566","article-title":"Mode of presentation and multisystem involvement in Beh\u00e7et's disease: the influence of sex and age of disease onset","volume":"25","author":"Krause","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ncprheum0436","article-title":"Behcet's syndrome: disease manifestations, management, and advances in treatment","volume":"3","author":"Yazici","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib8","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","article-title":"Interferon therapy in rheumatic diseases: state of the art 2010","volume":"22","author":"Kotter","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2010.09.002_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.61.suppl_2.ii51","article-title":"Behcet's disease: a new target for anti-tumor necrosis factor treatment","volume":"61","author":"Sfikakis","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib10","first-page":"128","article-title":"Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bech\u00e7et's disease; soluble TNFR-75 as a biological marker of disease activity","volume":"24","author":"Turan","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/09629350220131935","article-title":"Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh\u00e7et's disease","volume":"11","author":"Evereklioglu","year":"2002","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis","volume":"33","author":"Santos Lacomba","year":"2001","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib13","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib15","first-page":"185","article-title":"The treatment of recurrent uveitis with TNF-alpha inhibitors","volume":"56","author":"Falappone","year":"2004","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib16","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.ajo.2004.04.066","article-title":"Infliximab for chronic cystoid macular edema associated with uveitis","volume":"138","author":"Markomichelakis","year":"2004","journal-title":"Am J Ophthalmol"},{"issue":"4 Suppl 34","key":"10.1016\/j.semarthrit.2010.09.002_bib17","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Beh\u00e7et's disease","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0755-4982(05)84079-5","article-title":"Infliximab in the treatment of posterior uveitis in Beh\u00e7et's disease","volume":"34","author":"Lanthier","year":"2005","journal-title":"Presse Med"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1157\/13083329","article-title":"Medium-long term treatment with infliximab and methotrexate in posterior and\/or chronic uveitis refractory to conventional treatment","volume":"126","author":"Cobo-Ib\u00e1\u00f1ez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/kel030","article-title":"Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis","volume":"45","author":"Saurenmann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/rheumatology\/kem103","article-title":"Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet's syndrome","volume":"46","author":"Seyahi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib23","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/039463200902200235","article-title":"Safety and efficacy of etanercept in children with juvenile-onset Behcets disease","volume":"22","author":"Cantarini","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/jop.2008.0073","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Callejas-Rubio","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/jop.2007.0104","article-title":"Adalimumab therapy for refractory uveitis: a pilot study","volume":"24","author":"Diaz-Llopis","year":"2008","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib27","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib28","first-page":"875","article-title":"Effectiveness of infliximab in patients with Beh\u00e7et syndrome and severe uveoretinitis","volume":"134","author":"Merino","year":"2006","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib29","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/ard.2006.064279","article-title":"Adalimumab: a new modality for Beh\u00e7et's disease?","volume":"66","author":"van Laar","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Beh\u00e7et's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib31","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/ibd.20457","article-title":"Efficacy of infliximab for induction and maintenance of remission in intestinal Beh\u00e7et's disease","volume":"14","author":"Naganuma","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/03009740802366076","article-title":"Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study","volume":"38","author":"Lopez-Gonzalez","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2010.09.002_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":"Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behcet's disease","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib35","first-page":"438","article-title":"Treatment of Beh\u00e7et's disease with adalimumab","volume":"131","author":"Callejas-Rubio","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib38","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.eye.6701689","article-title":"Long-term treatment of refractory posterior uveitis with anti-TNF-alpha (infliximab)","volume":"19","author":"Benitez-del-Castillo","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib40","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib41","first-page":"427","article-title":"The efficacy of a single dose of infliximab in the treatment of Beh\u00e7et's disease uveitis","volume":"23","author":"Arayssi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib42","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib44","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10384-006-0425-y","article-title":"Infliximab treatment for ocular and extraocular manifestations of Beh\u00e7et's disease","volume":"51","author":"Accorinti","year":"2007","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib46","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","article-title":"Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial","volume":"29","author":"Al-Rayes","year":"2008","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib49","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kep126","article-title":"Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease","volume":"48","author":"Iwata","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib50","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","author":"Giardina","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib51","first-page":"87","article-title":"Effects and safety of infliximab administration in refractory uveoretinitis with Beh\u00e7et's disease","volume":"114","author":"Tanaka","year":"2010","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib52","first-page":"98","article-title":"Short-term trial of etanercept in Beh\u00e7et's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J Rheumatol"},{"issue":"4 Suppl 30","key":"10.1016\/j.semarthrit.2010.09.002_bib53","first-page":"S57","article-title":"Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Beh\u00e7et's disease","volume":"21","author":"Andonopoulos","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib54","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/keh445","article-title":"A case of Behcet's disease with scleromalakia perforans","volume":"44","author":"Sakellariou","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":"Infliximab for the threatment of posterior uveitis with retinal neovascularization in Behcet's disease","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bjo.2007.127522","article-title":"Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha","volume":"92","author":"Evereklioglu","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib57","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3748\/wjg.14.2912","article-title":"Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment","volume":"14","author":"Sari","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib58","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1469-0691.2007.01796.x","article-title":"Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment","volume":"13","author":"Mancini","year":"2007","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib59","article-title":"Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis","author":"Takase","year":"2009","journal-title":"Rheumatol Int"},{"issue":"4 Suppl 50","key":"10.1016\/j.semarthrit.2010.09.002_bib60","first-page":"S133","article-title":"Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Beh\u00e7et's disease","volume":"26","author":"Belzunegui","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib61","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","article-title":"Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Beh\u00e7et's disease: a case report","volume":"120","author":"Hassard","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","article-title":"Treatment of intestinal Beh\u00e7et's syndrome with chimeric tumour necrosis factor alpha antibody","volume":"49","author":"Travis","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib63","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s10350-004-6506-4","article-title":"Beh\u00e7et's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case","volume":"46","author":"Kram","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s10067-006-0410-3","article-title":"Successful treatment of life-threatening intestinal ulcer in Beh\u00e7et's disease with infliximab: rapid healing of Beh\u00e7et's ulcer with infliximab","volume":"26","author":"Ju","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib65","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","article-title":"Remission of intestinal Beh\u00e7et's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)","volume":"22","author":"Lee","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib66","article-title":"Late response to anti-TNF-alpha therapy in refractory mucocutaneous lesions of Beh\u00e7et's disease","author":"Aikawa","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et's disease is successfully treated with etanercept: further evidence for the value of TNF-alpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib68","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1136\/ard.2005.045195","article-title":"Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment","volume":"65","author":"Baki","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib69","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s10067-006-0426-8","article-title":"Pulmonary aneurysms and intracardiac thrombi due to Beh\u00e7et's disease in an African-American adolescent with oculocutaneous albinism","volume":"26","author":"Endo","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ard.61.6.560","article-title":"Anti-tumour necrosis factor monoclonal antibody treatment for ocular Beh\u00e7et's disease","volume":"61","author":"Triolo","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10067-009-1272-2","article-title":"Adalimumab treatment for life threatening pulmonary artery aneurysm in Beh\u00e7et disease: a case report","volume":"29","author":"Lee","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/0003-4819-135-1-200107030-00010","article-title":"Treatment of complicated sarcoidosis with Infliximab anti-tumour necrosis factor-alpha therapy","volume":"135","author":"Yee","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib73","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1572-0241.2003.07368.x","article-title":"Retinal vein thrombosis after Infliximab (Remicade) treatment for Crohn's disease","volume":"98","author":"Puli","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib74","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","article-title":"Remission of Beh\u00e7et's syndrome with tumour necrosis factor alpha blocking therapy","volume":"60","author":"Goossens","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","article-title":"Treatment of recalcitrant orogenital ulceration of Beh\u00e7et's syndrome with infliximab","volume":"40","author":"Robertson","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib76","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.11204","article-title":"Treatment with infliximab for a child with Beh\u00e7et's disease","volume":"49","author":"Saulsbury","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib77","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","article-title":"Successful treatment of genital ulcers with infliximab in Behcet's disease","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib78","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1365-2133.2005.06914.x","article-title":"Infliximab treatment for severe orogenital ulceration in Beh\u00e7et's disease","volume":"153","author":"Connolly","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4 Suppl 45","key":"10.1016\/j.semarthrit.2010.09.002_bib79","first-page":"S99","article-title":"Infliximab for the treatment of resistant oral ulcers in Beh\u00e7et's disease: a case report and review of the literature","volume":"25","author":"Almoznino","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib80","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s10350-006-0813-x","article-title":"Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Beh\u00e7et's disease: report of a case","volume":"50","author":"Byeon","year":"2007","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib81","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1572-0241.2003.07317.x","article-title":"Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab","volume":"98","author":"Mussack","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib82","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","article-title":"Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Beh\u00e7et's syndrome","volume":"62","author":"Licata","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib83","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1136\/jnnp.2004.055434","article-title":"Efficacy of TNF \u03b1 blockade in cyclophosphamide resistant neuro-Beh\u00e7et disease","volume":"76","author":"Ribi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib84","first-page":"181","article-title":"Successful treatment of long-standing neuro-Beh\u00e7et's disease with infliximab","volume":"32","author":"Sarwar","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib85","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.2006.056804","article-title":"Successful treatment of refractory neuro-Behcet's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile","volume":"66","author":"Fujikawa","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 50","key":"10.1016\/j.semarthrit.2010.09.002_bib86","first-page":"S128","article-title":"Worsening of osteomalacia in a patient successfully treated for neuro-Beh\u00e7et's disease with infliximab","volume":"26","author":"Madanat","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib87","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000289205","article-title":"The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions","volume":"11","author":"Sfikakis","year":"2010","journal-title":"Curr Dir Autoimmun"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clineuro.2007.10.005","article-title":"Anti-tumor necrotic factor antibody for treatment of neuro-Beh\u00e7et's disease, a case report","volume":"110","author":"Borhani Haghighi","year":"2008","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib89","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/j.ijid.2008.11.007","article-title":"Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease","volume":"13","author":"Kluger","year":"2009","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib90","first-page":"S65","article-title":"Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease","volume":"25","author":"Elezoglou","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib91","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib92","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Behcet's disease\u2014review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib93","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Behcet's disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib94","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"K\u00f6tter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib95","article-title":"Infliximab versus corticosteroids for sight-threatening panuveitis relapse in Beh\u00e7et's disease: a comparative 4-week study","author":"Markomichelakis","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib96","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/0-306-48382-3_112","article-title":"The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Beh\u00e7et's disease","volume":"528","author":"Morris","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2010.09.002_bib97","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/rheumatology\/keh056","article-title":"Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Beh\u00e7et's disease","volume":"43","author":"Y\u00fccel","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Suppl 42","key":"10.1016\/j.semarthrit.2010.09.002_bib98","first-page":"S128","article-title":"Urticaria and angioedema in a patient with Beh\u00e7et's disease treated with adalimumab","volume":"24","author":"S\u00e0nchez-Cano","year":"2006","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017210001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T01:37:27Z","timestamp":1559871447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017210001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0049017210001952"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2010.09.002","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}